REG - Kromek Group PLC - Notice of Results

KromekAnnouncement

14/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211214:nRSN5080Va&default-theme=true

RNS Number : 5080V  Kromek Group PLC  14 December 2021

14 December 2021

 

Kromek Group plc

("Kromek" or the "Group")

 

Notice of Results

 

Kromek (AIM: KMK), a leading developer of radiation and bio-detection
technology solutions for the advanced imaging and CBRN segments, gives notice
that it will be announcing its interim results for the six months ended 31
October 2021 on 18 January 2022.

 

Dr Arnab Basu, Chief Executive Officer, and Paul Farquhar, Chief Financial
Officer, will be hosting a presentation to analysts at 9.30am GMT on the day
via webcast. To register to participate, please contact:
amysmart@luther.co.uk.

 

 

For further information, please contact:

 

 Kromek Group plc
 Arnab Basu, CEO                                       +44 (0)1740 626 060

 Paul Farquhar, CFO

 Cenkos Securities plc (Nominated Adviser and Broker)
 Giles Balleny/Camilla Hume (NOMAD)                    +44 (0)20 7397 8900

 Julian Morse (Sales)

 Luther Pendragon (Financial PR)
 Harry Chathli                                         +44 (0)20 7618 9100

 Claire Norbury

 

About Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN segments.
Headquartered in County Durham, UK, Kromek has manufacturing operations in the
UK and US, delivering on the vision of enhancing the quality of life through
innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation settings.

 

In CBRN, the Group provides nuclear radiation detection solutions to the
global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation
technology, are primarily used to protect critical infrastructure and urban
environments from the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN segment. These
consist of fully automated and autonomous systems to detect a wide range of
airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

Further information is available at www.kromek.com (http://www.kromek.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFFEFADEFSELE